What were Concord Biotech Ltd's latest quarterly results?
Concord Biotech Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -37.1%
- Revenue Growth YoY: -24.2%
- Operating Margin: 36.0%
Concord Biotech Ltd: Stock Analysis & Fundamentals
Updated this weekConcord Biotech Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 51.3. ROE: 13.8%. This stock is not currently in the Nifty 500 momentum outperformers list.
Concord Biotech Ltd Key Facts
What's Happening
🏦Virtually debt-free company
Key Numbers
Current Price
₹1,291
Dividend Yield
0.83%
Market Cap
13.5K Cr
Valuation
N/AOther Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Concord Biotech Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Concord Biotech Ltd's current PE ratio?
Concord Biotech Ltd's current PE ratio is 51.3x.
- Current PE: 51.3x
- Market Cap: 13.5K Cr
- Dividend Yield: 0.83%
What is Concord Biotech Ltd's price-to-book ratio?
Concord Biotech Ltd's price-to-book ratio is 6.7x.
- Price-to-Book (P/B): 6.7x
- Book Value per Share: ₹193
- Current Price: ₹1291
Is Concord Biotech Ltd a fundamentally strong company?
Concord Biotech Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 18.0%
Is Concord Biotech Ltd debt free?
Concord Biotech Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹2 Cr
What is Concord Biotech Ltd's return on equity (ROE) and ROCE?
Concord Biotech Ltd's return ratios over recent years
- FY2024: ROCE 28.0%
- FY2025: ROCE 28.0%
- FY2026: ROCE 18.0%
Is Concord Biotech Ltd's cash flow positive?
Concord Biotech Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹267 Cr
- Free Cash Flow (FCF): ₹124 Cr
- CFO/PAT Ratio: 103% (strong cash conversion)
What is Concord Biotech Ltd's dividend yield?
Concord Biotech Ltd's current dividend yield is 0.83%.
- Dividend Yield: 0.83%
- Current Price: ₹1291
Who holds Concord Biotech Ltd shares — promoters, FII, DII?
Concord Biotech Ltd's shareholding pattern (Mar 2026)
- Promoters: 44.1%
- FII (Foreign): 7.8%
- DII (Domestic): 9.2%
- Public: 38.9%
Is promoter holding increasing or decreasing in Concord Biotech Ltd?
Concord Biotech Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 44.1% (Mar 2026)
- Previous Quarter: 44.1% (Dec 2025)
- Change: 0.00% (stable)
Is Concord Biotech Ltd a new momentum entry or an established outperformer?
Concord Biotech Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Concord Biotech Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Concord Biotech Ltd may be worth studying
- Cash flow is positive — CFO ₹267 Cr
What is the investment thesis for Concord Biotech Ltd?
Concord Biotech Ltd investment thesis summary:
What is the future outlook for Concord Biotech Ltd?
Concord Biotech Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.